Wegovy’s Newly Verified Heart Benefits Under Medicare Review

Medicare may soon be required to cover the blockbuster weight-loss drug Wegovy for heart disease patients with obesity after US regulators approved an expanded label last week.

The Centers for Medicare and Medicaid Services “is reviewing the FDA’s action to expand use of Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight,” a spokesperson said in an email. The agency, known as CMS, will share additional information as appropriate, according to the spokesperson.

Medicare, the federal health insurance program for the elderly and some people on long-term ...